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Heart failure (HF) and cancer represent two major causes of 
morbidity and mortality in developed countries.1,2 The prevalence 
of these conditions is growing as the age of the population and 
the burden of shared risk factors, such as diabetes and obesity, 
are constantly increasing. In past decades, the field of cardio-
oncology has predominantly focused on prevention and treatment 
of cardiovascular disease in cancer survivors, who are particularly 
prone to developing HF as a result of the cardiotoxicity of many 
antineoplastic agents and the clustering of cardiovascular risk factors 
in oncological patients.3 
The co-occurrence of cancer and HF represents a major clinical 
problem, because each disease impinges on the treatment of the other 
disease, and consequently, has a detrimental impact on quality of life 
and survival.4,5 In this scenario, the interaction between cardiologists 
and oncologists is indispensable to ensure optimal management of 
patients affected by both conditions.4 In recent years, a previously 
unappreciated connection between cancer and cardiovascular disease 
emerged from epidemiological studies reporting an increased risk of 
incident cancer in HF patients.6–9 Although the cause of this association 
is not yet resolved, it has been proposed that HF might represent 
a cancer-predisposing condition.9–11 Another intriguing possibility is 
that the co-occurrence of HF and cancer is promoted by a common 
pathological milieu characterised by a state of chronic low-grade 
inflammation, which predisposes to both diseases.10
In this review, we provide an overview of the mechanisms underlying 
the bidirectional relationship between HF and cancer (Figure 1). 
Whereas pathways driving the increased risk of cardiovascular disease 
in cancer patients have been the subject of intense investigation, 
mechanistic links driving the increased risk of malignancy in HF 
patients have not been elucidated so far. In this respect, we outline 
below two non-mutually exclusive hypotheses that should be 
addressed by future preclinical and clinical studies. 
Incident Heart Failure in Cancer 
Advances in the treatment of cancer have reduced the morbidity 
and mortality associated with many types of neoplasms. 
However, oncological therapies, including chemotherapy, 
radiotherapy, and newer-generation targeted therapies, may have 
toxic effects on the heart (Figure 2), up to causing HF either 
acutely, e.g. by causing acute coronary syndromes or myocarditis-
like syndromes, or chronically, by directly impacting on cardiac 
myocyte function.12 Because of the substantial improvements in 
the management of most types of cancer, these complications may 
have a major impact on the prognosis of patients with malignancy; 
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in fact, they may become the primary clinical problem when cancer 
is stably controlled or cured.13 
A far less common cause of HF in cancer patients is the secretion 
of cardiotoxic substances, such as light-chain immunoglobulins or 
vasoactive mediators associated with monoclonal B-cell proliferation 
and neuroendocrine tumours (NETs), respectively.
Chemotherapy- and Radiotherapy-induced Heart 
Failure
Anthracyclines, a class of chemotherapeutic agents commonly used 
for the treatment of solid and haematologic malignancies, were 
the first antineoplastic drugs for which a cardiotoxic effect was 
recognised.14 Anthracycline cardiotoxicity may manifest as HF with 
acute or subacute onset, but may also lead to subclinical left ventricular 
dysfunction insidiously progressing to HF over the course of several 
years after exposure to the drug.15 The incidence of anthracycline-
related cardiac dysfunction is dose-dependent, and ranges from 5% 
at a cumulative dose of 400 mg/m2 to 26% for 550 mg/m2.16 However, 
a subclinical decrease in systolic function has also been reported for 
lower doses in survivors of acute lymphoblastic leukaemia.17 
The antiproliferative effect of anthracyclines stems from their 
ability to intercalate into nuclear DNA and block topoisomerase 2 
activity, consequently inhibiting DNA replication and transcription. 
Furthermore, these agents cause damage to cellular components 
by forming complexes with iron and thereby inducing production 
of reactive oxygen species (ROS). Preclinical studies indicated that 
oxidative stress might represent the dominant driver of anthracyclines 
cardiotoxicity, but ROS scavengers failed to prevent doxorubicin-
induced cardiomyopathy in humans.12,18 Moreover, iron chelating 
agents did not show any cardioprotective effect in a rat model of 
anthracycline toxicity.19 A recent experimental study demonstrated 
that cardiac topoisomerase is a key mediator of doxorubicin-
induced cardiotoxicity, possibly accounting for the lack of efficacy 
of antioxidant agents in this setting. In fact, doxorubicin triggers 
apoptosis and transcriptomic remodelling in a topoisomerase-
dependent manner, ultimately impacting on oxidative phosphorylation 
and mitochondrial biogenesis.20 
Overall, in spite of a large body of preclinical research addressing 
the mechanisms of anthracyclines cardiotoxicity, pharmacological 
approaches aimed at alleviating this important side-effect are limited 
to a single agent, dexrazoxane, which achieves its cardioprotective 
activity via topoisomerase inhibition.21 Recently, inhibition of the 
multifunctional kinase, phosphoinositide 3-kinase gamma, was 
shown to enhance removal of damaged mitochondria in a mouse 
model of doxorubicin-induced HF, pinpointing a potential therapeutic 
strategy to protect the heart against anthracyclines toxicity.22
Since the discovery of anthracyclines-related cardiotoxicity, many other 
chemotherapeutic agents have been associated with the development 
of cardiomyopathy. Alkylating agents, such as cyclophosphamide 
and ifosfamide, inhibit cell proliferation by inducing DNA damage. 
Cardiotoxicity associated with these drugs manifests predominantly 
as conduction disorders and pericarditis, and high-dose regimens can 
lead to myocarditis and HF.23,24 Experimental evidence suggests that 
alkylating agents cause endothelial and myocyte damage secondary 
to the accumulation of toxic metabolites.25 Antimetabolites, such as 
5-fluorouracil and its pro-drug capecitabine, achieve their cardiotoxic 
effects mainly by triggering coronary artery vasospasm,12 but preclinical 
studies indicate that these agents might also be directly toxic to 
endothelial cells and cardiac myocytes by triggering ROS production 
and inducing mitochondrial dysfunction.26,27
Radiation therapy represents a standard approach for breast cancer 
treatment, and often involves the exposure of the heart to high 
radiation doses. Pericardial fibrosis is the most common radiotherapy-
related lesion, but radiation therapy also damages the myocardium.28 
Indeed, although cardiac myocytes are non-proliferating cells, and thus 
relatively resistant to radiation damage, emerging evidence indicates 
that chest irradiation can also lead to cardiomyopathy, and preclinical 
studies pinpointed ROS production with subsequent activation of Ca2+/
calmodulin-dependent protein kinase II as a key mediator of radiation 
damage to cardiac myocytes.29 
In contrast to cardiac myocytes, endothelial cells are continuously 
proliferating, and thereby more susceptible to radiation damage. 
Preclinical studies indicate that the primary lesion associated with 
radiation therapy is endothelial apoptosis, which might account for 
the clinical observation of accelerated atherosclerosis in patients 
receiving radiation therapy to the chest.30,31 In fact, cardiac radiation 
dose correlates with the subsequent risk of ischaemic heart disease in 
breast cancer patients, and even low levels of exposure heighten the 
risk of coronary events.32 Furthermore, a recent study observed that 
radiation therapy in breast cancer patients leads to a dose-dependent 
increase in the relative risk of HF with preserved ejection fraction 
(HFpEF).33 The latter observation corroborates the model according to 
which microvascular endothelial dysfunction represents a key factor in 
the pathogenesis of HFpEF.34 
Antineoplastic Targeted Therapy-induced Heart Failure 
Trastuzumab is a humanised monoclonal antibody targeting the 
human epidermal growth factor receptor (HER)2, a member of the 
ErbB family of receptors, which is overexpressed in a subset of 
breast cancer patients.35 Trastuzumab was initially approved as a 
first-line treatment for metastatic breast cancer, and is currently 
indicated for the treatment of HER2-positive breast and gastric 
cancer. The addition of trastuzumab to adjuvant therapy for breast 
cancer resulted in asymptomatic left ventricular dysfunction or 
overt HF in up to 18% and 4% of treated patients, respectively.36,37 
The observation of trastuzumab cardiotoxicity led scientists to 
Figure 1: Mechanisms Underlying the Bidirectional 
Relationship Between Heart Failure and Cancer
From cancer to heart failure:
From heart failure to cancer:
• Cancer therapy-related cardiotoxicity
• SNS and RAAS hyperactivation
• Secreted factors
• Amyloidosis – carcinoid heart disease
Cancer Heart failure
Inammation
RAAS = renin–angiotensin–aldosterone system; SNS = sympathetic nervous system.
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interrogate the function of HER2 signalling in preclinical models 
of cardiac disease, revealing that this pathway plays an important 
homeostatic role,38 and is activated in response to cardiac injury; for 
example, following ischaemia, pressure overload, and anthracycline 
toxicity (reviewed by De Keulenaer et al.39). Therefore, HER2 inhibition 
does not cause myocardial damage directly, but rather, blocks an 
important adaptive signalling pathway and thereby renders the heart 
more susceptible to pathological stressors. Accordingly, trastuzumab-
induced cardiac dysfunction is usually completely reversible 4–6 
weeks after discontinuation of the drug. However, for reasons yet to 
be fully elucidated, cardiac function is irreversibly compromised in a 
minority of patients treated with trastuzumab.36 
Vascular endothelial growth factor (VEGF) is a key regulator of 
angiogenesis, the process of new blood vessel formation that sustains 
tumour growth when its enlargement precludes diffusion of nutrients 
and oxygen from pre-existing vessels.40 VEGF signalling has become 
the target of several antineoplastic agents, such as the humanised 
antibody bevacizumab and the tyrosine kinase inhibitors (TKI) sunitinib 
and sorafenib. Drugs targeting VEGF signalling have been linked to a 
wide spectrum of cardiovascular side-effects, such as hypertension, 
thromboembolism, and cardiomyopathy.41,42 In patients treated 
with anthracyclines for breast cancer, concurrent treatment with 
bevacizumab increased HF incidence from 4% to 14%.43 Experimental 
evidence indicates that the effects of agents inhibiting VEGF signalling 
on blood pressure and thromboembolic risk might be mediated by 
decreased production of two vasodilators, nitric oxide and prostacyclin, 
and increased production of the potent vasoconstrictor, endothelin-1, 
whose circulating levels were found elevated in patients treated 
with sunitinib.44–46 Sunitinib and sorafenib are only two examples of 
small-molecule TKI for which cardiotoxic effects were recognised. 
The number of TKI approved for cancer treatment is steadily growing, 
and cardiovascular side-effects have been reported for many of 
these drugs, such as the ABL inhibitors dasatinib and nilotinib or 
the multi-kinase inhibitor regorafenib.47 Although the incidence of 
cardiovascular side-effects with these drugs is relatively low, the 
underlying mechanisms need to be further clarified to improve the 
safety of TKI currently under development. 
Finally, cardiotoxic effects have also been associated with proteasome 
inhibitors, a class of antineoplastic agents used in the treatment 
of multiple myeloma and other hematologic malignancies. The first 
approved agent of this class, bortezomib, might cause HF in up to 4% 
of treated patients, and the second-generation proteasome inhibitor, 
carfilzomib, is associated with an even higher cardiotoxicity, with 
an incidence of cardiovascular adverse events of 18% according to 
a recent meta-analysis.48,49 The ubiquitin–proteasome system plays 
an important adaptive role in the myocardium, and its inhibition is 
sufficient to cause cardiac dysfunction in pigs.50 Therefore, cardiotoxicity 
associated with proteasome inhibitors is likely directly related to their 
mechanism of action.
Cancer-related Heart Failure 
HF can also be the consequence of two rare cardiomyopathies, i.e. 
light-chain amyloidosis and carcinoid heart disease (Figure 2), although 
this happens more rarely than following oncological treatments.
Amyloidosis is a disorder characterised by extracellular deposition of 
a proteinaceous material, coined as amyloid, derived from misfolding 
of a variety of precursor proteins.51 Amyloidosis is a systemic disorder 
and can affect several organs, but amyloid involvement of the 
heart portends by far the worst prognosis of any other type of 
organ involvement. Cardiac amyloidosis involves both myocardium 
and cardiac valves, and manifests as restrictive cardiomyopathy 
inexorably progressing to overt HF (reviewed by Falk et al.52 and Gertz 
et al.53). Amyloid light-chain (AL) amyloidosis, which is secondary 
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to overproduction of immunoglobulin light chain by plasma cell 
malignancies, is the most severe form of the disease, with a median 
survival of 6 months from HF onset if the underlying dyscrasia is left 
untreated.54 Cardiac AL amyloidosis leads to a more severe form of 
HF despite a lower degree of cardiac hypertrophy, suggesting that AL 
amyloid protein might have direct toxic effects on cardiac myocytes.55 
Preclinical studies indicate that oxidative stress might represent a 
dominant driver of AL amyloid cardiotoxic activity.56 Treatment of 
cardiac AL amyloidosis is currently limited to optimal management of 
HF and the underlying amyloidogenic malignancy, whereas therapeutic 
approaches directly targeting AL deposition in the myocardium are not 
currently available in the clinical setting.52 
A rare form of cancer-related cardiac involvement is carcinoid heart 
disease, which is caused by NETs releasing vasoactive mediators, such 
as serotonin, bradykinin, and histamine. NETs are rare neoplasms arising 
from enterochromaffin cells of the gastrointestinal or respiratory tract. 
Because the mediators released by NETs are efficiently inactivated 
in the liver and the pulmonary vasculature, carcinoid heart disease 
usually arises from gastrointestinal NET upon their metastasisation 
to the liver and predominantly affects the right ventricle, whereas 
left ventricular involvement is observed in 5–10% of cases and is 
usually associated with bronchial carcinoids.57,58 The typical feature 
of carcinoid heart disease is the formation of endomyocardial fibrotic 
plaques, ultimately leading to right-sided HF. Furthermore, fibrotic 
remodelling often also involves the tricuspid valve, causing valvular 
regurgitation, which contributes to right ventricular decompensation. 
Medical therapy for carcinoid syndrome is limited to symptomatic relief 
with somatostatin analogues, which are ineffective toward myocardial 
and valvular involvement.59
While AL amyloidosis and carcinoid heart disease are the only forms of 
cancer-elicited HF observed in the clinical arena so far, experimental 
work suggests that other malignancies might affect cardiac function 
via the release of cardiotoxic oncometabolites. Mutations of the Krebs 
cycle enzyme, isocitrate dehydrogenase, have been identified in a 
subset of patients with myeloid leukaemia. In rats, this mutation leads 
to accumulation and release of D-2-hydroxyglutarate from malignant 
cells, and this oncometabolite impairs cardiac Krebs cycle activity and 
contractile function.60 
Incident Cancer in Heart Failure
Recent epidemiological studies revealed that HF patients carry a 
higher risk of incident cancer compared with individuals without 
HF, drawing attention toward another potential link between HF and 
cancer. This finding was first reported in a community-based case–
control study, and subsequently confirmed in a large prospective 
study based on the Danish national registries.6,7 Furthermore, a 
prospective cohort study demonstrated that patients developing 
HF following acute MI have an increased risk of incident cancer 
compared with those who do not develop HF after MI.8 This 
association might be accounted for by a detection bias due to 
intensified medical observation following HF diagnosis. However, 
the increased risk of incident cancer was observed after the second 
year after HF diagnosis, and the association persisted after excluding 
cancer diagnoses made in the first years of follow-up.
 Furthermore, cancer and HF share several risk factors, such as 
diabetes and obesity, which might partly explain the association 
between HF and increased risk of malignancy. In the above-
mentioned studies, however, the likelihood of receiving a diagnosis 
of cancer remained higher in HF patients after adjusting for shared 
risk factor. Another possibility is that the increased risk of incident 
cancer is driven by a pro-oncogenic effect of HF medications, but 
recent meta-analyses addressing this issue do not support this 
concept.61 On these grounds, the present authors and other authors 
have put forward two non-mutually exclusive hypotheses on how 
HF might lead to an increased risk of cancer, which are discussed in 
detail below.9,10
A third potential mechanism was recently elucidated in a preclinical 
study that demonstrated that ischemic HF enhances tumour growth 
via release of mitogenic factors by the failing myocardium.11 In that 
study, MI was induced in mice via coronary artery ligation, and 
infarcted hearts were transplanted in the cervical region of APCmin mice, 
which are genetically predisposed to develop colorectal neoplasms. 
Intriguingly, mice transplanted with an infarcted heart developed a 
higher tumour burden compared with mice receiving a sham-operated 
heart. Because recipient mice retained their native healthy hearts, the 
increase in tumour load could not be attributed to haemodynamic 
impairment related to HF, but was shown to depend on the mitogenic 
protein, serpinA3, secreted by the failing myocardium. The translational 
relevance of this mechanism is underscored by the observation that 
circulating levels of serpinA3 are increased in chronic HF patients.11 
Overall, the results of that study strongly support the concept that a 
diagnosis of HF represents a risk factor for incident cancer.
The Neurohormonal Hypothesis 
Hyperactivation of the sympathetic nervous system (SNS) and 
renin–angiotensin–aldosterone system (RAAS) is a hallmark of HF 
with reduced ejection fraction (HFrEF), and substantially contributes 
to episodes of decompensation as well as to cardiac death. 
Indeed, medical therapy of HFrEF currently relies on neurohormonal 
inhibitors: blockers of the beta-adrenergic receptors (AR), through 
which the catecholamines epinephrine and norepinephrine transmit 
SNS signals; inhibitors of the angiotensin-converting enzyme that 
synthesises angiotensin II (AngII); and antagonists of the AngII or 
aldosterone receptor.62 
The hypothesis that neurohormonal activation may also account for 
the increased risk of cancer observed in HF finds its background 
in a large body of experimental data demonstrating that SNS and 
RAAS activation promote cancer progression and dissemination 
via multiple mechanisms. The pro-oncogenic effects of the SNS are 
predominantly mediated by beta-AR expressed by both cancer cells 
and, more importantly, non-malignant cells constituting the tumour 
microenvironment. Specifically, beta-AR signalling was demonstrated 
to favour tumour growth, induce formation of blood and lymphatic 
vessels, and promote remodelling of the extracellular matrix, ultimately 
leading to tissue invasion and metastatic dissemination in vivo.63 
Similarly, AngII promotes tumour vascularisation and invasiveness via 
type 1 AngII receptors.64 
An important caveat is that, although SNS and RAAS activation has 
also been described in HFpEF patients, the latter do not benefit from 
treatment with beta-AR blockers and RAAS inhibitors, indicating 
that the role of neurohormonal activation in the progression of 
HFpEF is not as relevant as in HFrEF.65,66 Two of the epidemiological 
studies discussed above included a substantial proportion of HFpEF 
patients, and cancer incidence was independent of left ventricular 
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ejection fraction.6,9 Because neurohormonal hyperactivation might 
not account for the higher incidence of cancer observed in HFpEF, we 
hypothesise that other factors are involved in this subset of patients.
The ‘Inflammatory Milieu’ Hypothesis
Independent of its aetiology, HF is associated with an increase 
in circulating and intramyocardial levels of pro-inflammatory 
cytokines, such as tumour necrosis factor-alpha, interleukin-1, and 
interleukin-6.67–70 Inflammation is pivotal to the pathogenesis of 
atherosclerosis, which underlies the development of ischemic heart 
disease, the most common cause of HF.71 In turn, myocardial injury 
triggers immune system activation, inducing cytokine release, and 
thereby fostering a vicious cycle of self-sustained inflammation. 
Furthermore, it has been hypothesised that microvascular endothelial 
inflammation might decrease myocardial nitric oxide release, thereby 
inducing cardiac myocyte hypertrophy and impairing relaxation, which 
is a hallmark of HFpEF.34 
Indeed, HFpEF patients display elevated concentrations of galectin-3, 
an inflammatory mediator associated with myocardial fibrosis, 
and pentraxin 3, an inflammatory marker that was observed to 
correlate with left ventricular diastolic dysfunction.72,73 Furthermore, 
circulating levels of inflammatory markers (tumour necrosis factor-
alpha, transforming growth factor-beta, C-reactive protein, procollagen 
type 1 carboxy-terminal propeptide) were found to be elevated, and 
correlated with asymptomatic diastolic dysfunction in patients with 
metabolic syndrome and hypertension.74 Altogether, a wealth of clinical 
studies indicate that HFrEF and HFpEF are associated with a state 
of mild chronic systemic inflammation, but it is currently unresolved 
whether the latter is a cause or consequence of cardiac dysfunction. 
In contrast, chronic inflammation is considered carcinogenic and 
capable of boosting the transition from early-stage tumours to overt 
malignancies.75 In principle, therefore, inflammation might mediate 
the association of both HFrEF and HFpEF with incident cancer. 
Although preclinical studies addressing this hypothesis are lacking, 
this model is corroborated by the results of the Canakinumab Anti-
Inflammatory Thrombosis Outcome Study (CANTOS) trial.76 In that 
study, the interleukin-1beta-targeting antibody, canakinumab, reduced 
the rate of recurrent cardiovascular events in patients with previous 
MI. Intriguingly, additional analyses revealed that treatment with 
canakinumab was associated with a dose-dependent trend toward 
reduction of hospitalisation for HF, which was independent of prior 
HF history, and a lower risk of incident lung cancer.77,78 Altogether, 
the results of the CANTOS trial strongly support the concept that 
chronic low-grade inflammation represents a fertile substrate for the 
progression of HF and cancer. 
The striking results of the CANTOS trial stand to some degree at 
odds with studies using broad-spectrum anti-inflammatory agents, 
namely the tumour necrosis factor-alpha inhibitors, etanercept and 
infliximab, and the immune-system suppressant, methotrexate, 
which did not detect any effect of these drugs on cardiovascular 
events.77,79,80 An important difference between these studies and 
the CANTOS trial is that only the latter enrolled patients with 
modestly elevated C-reactive protein levels, reflecting a state of mild 
systemic inflammation. Furthermore, although excess inflammation is 
undoubtedly detrimental, cytokine signalling also mediates adaptive 
responses in the heart, and future studies should be aimed to more 
precisely identify signalling pathways associated with maladaptive 
processes driving the progression of HF.81,82
Finally, HF-related inflammation might foster cancer in an indirect way. 
For instance, a decline in the number of naïve T  cells, and a marked 
increase in highly differentiated effector and memory T  cells was 
recently observed in patients with HF, and is related to elevated levels of 
interleukin-6.83 These features are consistent with immunosenescence, 
which consists of the deterioration of both adaptive and innate 
immunity, and, given the role played by the immune system in malignant 
cell elimination, may partly account for the increase in cancer incidence 
in HF, as it has been postulated for ageing.84
Conclusion
Until now, the main focus of cardio-oncology has been the prevention 
and treatment of cardiotoxic effects of chemotherapeutic agents. In 
this context, elucidation of the underlying mechanisms is instrumental 
to the development of strategies to prevent chemotherapy-related 
cardiomyopathy. While this avenue of research is far from being exhausted 
as a result of the staggering growth of novel anticancer targeted 
therapies, a new exciting area of cardio-oncology opens up in front of 
us, inspired by several lines of evidence linking the pathophysiology 
of HF to the development and progression of malignancy. 
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